search
Back to results

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

Primary Purpose

Sickle Cell Disease

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
NDec - oral decitabine-tetrahydrouridine
HU - Hydroxyurea
Placebo
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sickle Cell Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age above or equal to 18 years at the time of signing informed consent
  • Confirmed diagnosis of SCD (including HbSS, HbSC, HbSβ0 thalassaemia and HbSβ+ thalassaemia)
  • 2-10 episodes of documented vaso-occlusive crisis (VOCs) within the last 12 months prior to the screening visit
  • Haemoglobin greater than or equal to 5.0 g/dL and below or equal to 10.5 g/dL at visit 1
  • Reticulocyte count above upper limit of the normal (ULN) at visit 1
  • Body weight 40 to 125 kg (inclusive).

Exclusion Criteria:

  • Patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received RBC or whole blood transfusion for any reason within 28 days of visit 1
  • Receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing ICF, or planned treatment with these agents during the trial
  • Receipt of voxelotor, crizanlizumab or L-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial
  • Platelet count greater than 800 x 10^9/L at visit 1
  • Absolute neutrophil count below or equal to 1.5 x 10^9/L at visit 1
  • Any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement
  • Female who is

    • pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration
    • child-bearing potential and not using highly effective methods of contraception and whose male partner is not using effective contraception, at screening and until 6 months after the last dose of trial product
  • Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to:

    • Six (6) months after the last dose of trial product for patients on NDec/Placebo
    • Six (6) months after the last dose of trial product for patients outside US and CA randomised to HU
    • Twelve (12) months after the last dose of trial product for patients randomised to HU in US and CA

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Active Comparator

Arm Label

HU-non-eligible - NDec plus placebo

HU-non-eligible - NDec plus NDec

HU-non-eligible - Placebo plus placebo

HU-active - NDec plus placebo

HU-active - NDec plus NDec

HU-active - HU

Arm Description

HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day

HU-non eligible patients randomised to treatment with NDec on both days

HU-non eligible patients randomised to treatment with placebo on both days

HU-active patients randomised to treatment with NDec on one day and placebo on the other day

HU-active patients randomised to treatment with NDec on both days

HU-active patients randomised to continue on open-label HU treatment

Outcomes

Primary Outcome Measures

Change in total haemoglobin
measured in g/dL

Secondary Outcome Measures

Cmax for decitabine from pharmacokinetic assessment
measured in ng/mL
Cmax for tetrahydrouridine from pharmacokinetic assessment
measured in ng/mL
Change in DNA methyltransferase 1 (DNMT1) activity
measured in MFI units
Change in cytidine deaminase (CDA) activity
µmol/L/min
Change in foetal haemoglobin (g/dL)
measured in g/dL
Change in foetal haemoglobin as a proportion of total haemoglobin (%HbF)
measured in %
Change in F-cell level as a proportion of total red blood cell (RBC) (%F-cells)
measured in %
Change in haemolysis measure: absolute reticulocyte count
measured in cells × 10^9/L
Change in haemolysis measure: indirect bilirubin
measured in mg/dL
Change in haemolysis measure: lactate dehydrogenase
measured in U/L
Number of vaso-occlusive crises
number of events
Number of acute chest syndrome
number of events
Number of RBC units transfused
measured in Units
Number of adverse events of grade 3 or higher
number of events

Full Information

First Posted
May 31, 2022
Last Updated
October 11, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05405114
Brief Title
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
Acronym
ASCENT1
Official Title
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2022 (Actual)
Primary Completion Date
November 15, 2023 (Anticipated)
Study Completion Date
February 28, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants get is decided by chance. Participants getting NDec and/or Placebo will get capsules to take twice weekly. The study will last for about a year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HU-non-eligible - NDec plus placebo
Arm Type
Experimental
Arm Description
HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day
Arm Title
HU-non-eligible - NDec plus NDec
Arm Type
Experimental
Arm Description
HU-non eligible patients randomised to treatment with NDec on both days
Arm Title
HU-non-eligible - Placebo plus placebo
Arm Type
Placebo Comparator
Arm Description
HU-non eligible patients randomised to treatment with placebo on both days
Arm Title
HU-active - NDec plus placebo
Arm Type
Experimental
Arm Description
HU-active patients randomised to treatment with NDec on one day and placebo on the other day
Arm Title
HU-active - NDec plus NDec
Arm Type
Experimental
Arm Description
HU-active patients randomised to treatment with NDec on both days
Arm Title
HU-active - HU
Arm Type
Active Comparator
Arm Description
HU-active patients randomised to continue on open-label HU treatment
Intervention Type
Drug
Intervention Name(s)
NDec - oral decitabine-tetrahydrouridine
Intervention Description
Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Intervention Type
Drug
Intervention Name(s)
HU - Hydroxyurea
Intervention Description
Participants will get capsules daily (oral administration) according to local labelling
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Primary Outcome Measure Information:
Title
Change in total haemoglobin
Description
measured in g/dL
Time Frame
From baseline (week 0) to week 24
Secondary Outcome Measure Information:
Title
Cmax for decitabine from pharmacokinetic assessment
Description
measured in ng/mL
Time Frame
At week 24
Title
Cmax for tetrahydrouridine from pharmacokinetic assessment
Description
measured in ng/mL
Time Frame
At week 24
Title
Change in DNA methyltransferase 1 (DNMT1) activity
Description
measured in MFI units
Time Frame
From baseline (week 0) to week 24
Title
Change in cytidine deaminase (CDA) activity
Description
µmol/L/min
Time Frame
From baseline (week 0) to week 24
Title
Change in foetal haemoglobin (g/dL)
Description
measured in g/dL
Time Frame
From baseline (week 0) to week 24
Title
Change in foetal haemoglobin as a proportion of total haemoglobin (%HbF)
Description
measured in %
Time Frame
From baseline (week 0) to week 24
Title
Change in F-cell level as a proportion of total red blood cell (RBC) (%F-cells)
Description
measured in %
Time Frame
From baseline (week 0) to week 24
Title
Change in haemolysis measure: absolute reticulocyte count
Description
measured in cells × 10^9/L
Time Frame
From baseline (week 0) to week 24
Title
Change in haemolysis measure: indirect bilirubin
Description
measured in mg/dL
Time Frame
From baseline (week 0) to week 24
Title
Change in haemolysis measure: lactate dehydrogenase
Description
measured in U/L
Time Frame
From baseline (week 0) to week 24
Title
Number of vaso-occlusive crises
Description
number of events
Time Frame
From baseline (week 0) to week 48
Title
Number of acute chest syndrome
Description
number of events
Time Frame
From baseline (week 0) to week 48
Title
Number of RBC units transfused
Description
measured in Units
Time Frame
From baseline (week 0) to week 48
Title
Number of adverse events of grade 3 or higher
Description
number of events
Time Frame
From baseline (week 0) to week 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age above or equal to 18 years at the time of signing informed consent Confirmed diagnosis of SCD (including HbSS, HbSC, HbSβ0 thalassaemia and HbSβ+ thalassaemia or other Sickle Cell disease variants) 2-10 episodes of documented vaso-occlusive crisis (VOCs) within the last 12 months prior to the screening visit Haemoglobin greater than or equal to 5.0 g/dL and below or equal to 10.5 g/dL at visit 1 Absolute reticulocyte count above upper limit of the normal (ULN) at visit 1 Body weight 40 to 125 kg (inclusive). Exclusion Criteria: Patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received RBC or whole blood transfusion for any reason within 28 days of visit 1 Receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing ICF, or planned treatment with these agents during the trial Receipt of voxelotor, crizanlizumab or L-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial Platelet count greater than 800 x 10^9/L at visit 1 Absolute neutrophil count below or equal to 1.5 x 10^9/L at visit 1 Any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement Female who is pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration child-bearing potential and not using highly effective methods of contraception and whose male partner is not using effective contraception, at screening and until 6 months after the last dose of trial product Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to: Six (6) months after the last dose of trial product for patients on NDec/Placebo Six (6) months after the last dose of trial product for patients outside US and CA randomised to HU Twelve (12) months after the last dose of trial product for patients randomised to HU in US and CA
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Novo Nordisk
Phone
(+1) 866-867-7178
Email
clinicaltrials@novonordisk.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency (dept. 2834)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36617
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Oakland
State/Province
California
ZIP/Postal Code
94609
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Torrance
State/Province
California
ZIP/Postal Code
90502-2004
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20060
Country
United States
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33023
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70002
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Madison
State/Province
Mississippi
ZIP/Postal Code
39110
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89135
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19134
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
London
State/Province
Ontario
ZIP/Postal Code
ON N6A 5W9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G2C4
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
La Tronche
ZIP/Postal Code
38700
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Lyon cedex 03
ZIP/Postal Code
69437
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Goudi
ZIP/Postal Code
11527
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Larissa
ZIP/Postal Code
41221
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Patra
ZIP/Postal Code
GR-26504
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Surat
State/Province
Gujarat
ZIP/Postal Code
395002
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Vadodara
State/Province
Gujarat
ZIP/Postal Code
390006
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560002
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560002
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kozhikode
State/Province
Kerala
ZIP/Postal Code
673008
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440003
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bhubaneswar
State/Province
Orissa
ZIP/Postal Code
751003
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Ranipet
State/Province
Tamil Nadu
ZIP/Postal Code
632517
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Vellore
State/Province
Tamil Nadu
ZIP/Postal Code
632004
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226014
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kolkatta
State/Province
West Bengal
ZIP/Postal Code
70014
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Nagpur
ZIP/Postal Code
440001
Country
India
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Genova
ZIP/Postal Code
16128
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Padova
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Verona
ZIP/Postal Code
37134
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Parktown, Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2193
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Adana
ZIP/Postal Code
01130
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Ankara
ZIP/Postal Code
06230
Country
Turkey
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Mersin
ZIP/Postal Code
33110
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cardiff
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
NW10 7NS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

We'll reach out to this number within 24 hrs